[{"id":"5281d885-db71-4720-b9bf-1c0b248f2e5b","acronym":"NCI-2022-04099","url":"https://clinicaltrials.gov/study/NCT05372614","created_at":"2022-05-13T12:54:23.489Z","updated_at":"2024-07-02T16:34:58.772Z","phase":"Phase 1","brief_title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","source_id_and_acronym":"NCT05372614 - NCI-2022-04099","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • CD4 • CASP3","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA","tags":["HER-2 • CD4 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 06/17/2024","primary_completion_date":" 06/17/2024","study_txt":" Completion: 06/17/2024","study_completion_date":" 06/17/2024","last_update_posted":"2024-06-05"},{"id":"a7437321-346d-40a3-ad9b-7749466b632b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02673398","created_at":"2021-01-17T17:30:55.191Z","updated_at":"2024-07-02T16:35:45.421Z","phase":"Phase 2","brief_title":"Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer","source_id_and_acronym":"NCT02673398","lead_sponsor":"City of Hope Medical Center","biomarkers":" ERBB3","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 L755P • ERBB3 mutation • HER-2 S310Y • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • ERBB3 V659E • HER-2 G778_S779insCPG • HER-2 L755_T759del • HER-2 A775 • HER-2 D769H • HER-2 R678Q • HER-2 R896C • HER-2 YVMA • ERBB3 L755S","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 L755P • ERBB3 mutation • HER-2 S310Y • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • ERBB3 V659E • HER-2 G778_S779insCPG • HER-2 L755_T759del • HER-2 A775 • HER-2 D769H • HER-2 R678Q • HER-2 R896C • HER-2 YVMA • ERBB3 L755S"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/02/2016","start_date":" 12/02/2016","primary_txt":" Primary completion: 03/12/2020","primary_completion_date":" 03/12/2020","study_txt":" Completion: 09/22/2022","study_completion_date":" 09/22/2022","last_update_posted":"2023-06-16"}]